MARKET

KMDA

KMDA

Kamada
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.71
-0.05
-0.74%
After Hours: 6.71 0 0.00% 16:41 12/04 EST
OPEN
6.72
PREV CLOSE
6.76
HIGH
6.75
LOW
6.64
VOLUME
58.02K
TURNOVER
--
52 WEEK HIGH
13.33
52 WEEK LOW
4.400
MARKET CAP
298.73M
P/E (TTM)
14.02
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Kamada (KMDA) A Good Stock To Buy Now?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Insider Monkey · 2d ago
Should Value Investors Consider Kamada (KMDA) Stock Now?
Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.
Zacks · 11/24 17:48
Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020.
GlobeNewswire · 11/11 12:00
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the third quarter ended September 30, 2020, prior to the open of the U.S. financial markets on Wednesday, November 11, 2020.
GlobeNewswire · 11/04 12:00
Kedrion's Partner, Kamada Ltd, Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy
LUCCA, , /PRNewswire/ -- The Israeli health authorities have signed a supply agreement for the investigational COVID-19 plasma-derived Immunoglobulin (IgG), to be supplied by Kamada Ltd., a biopharmaceutical company which is the partner of Kedrion Biopharma of in the development of the new anti-COVID-19 therapy. 
PR Newswire - PRF · 10/22 12:27
Kamada to supply investigational IgG product for COVID-19
Kamada (KMDA) +11% premarket, after signing an agreement with the Israeli Ministry of Health ((MoH)) to supply its anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) investigational product as a potential treatment for COVID-19 patients in Israel.The initial
Seekingalpha · 10/19 13:21
Kamada to supply Israel with its experimental COVID-19 treatment
Biopharmaceutical firm Kamada Ltd said on Monday it will supply Israel's Health Ministry with its experimental COVID-19 treatment for 500 patients in Israel. Kamada will manufacture the product from convalescent plasma collected by the Israeli National Blood Services and additional Israeli medical institutions. This initial supply is expected to generate $3.4 million in revenue for Kamada in the first quarter of 2021.
Reuters · 10/19 12:15
Kamada Announces Supply Agreement With Israeli Ministry Of Health For Its Investigational IgG Product For COVID-19; Initial Order Expected To Generate $3.4M In Revenue In First Quarter Of 2021
Treatment with Kamada's Investigational IgG Product Will Be Regulated by the Israeli Ministry of Health   Initial Order Sufficient to Treat 500 Patients Positive
Benzinga · 10/19 11:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KMDA. Analyze the recent business situations of Kamada through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KMDA stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 8.99M
% Owned: 20.19%
Shares Outstanding: 44.52M
TypeInstitutionsShares
Increased
11
132.16K
New
15
1.13M
Decreased
12
333.24K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Lilach Asher Topilsky
Chief Executive Officer
Amir London
Vice Chairman/Director
David Tsur
Chief Financial Officer
Chaime Orlev
Senior Vice President
Ruth Wolfson
Vice President - Operations
Barak Bashari
Vice President/Director of Human Resources
Shani Dotan
Vice President
Yael Brenner
Vice President
Orit Pinchuk
Vice President
Eran Schenker
Vice President
Michal Stein
Vice President
Pnina Strauss
Vice President
Naveh Tov
Vice President - Research & Development
Michal Ayalon
Vice President - Business Development
Eitan Kyiet
Director
Michael Berelowitz
Director
Jonathan Hahn
Director
Itzhak Krinsky
Director
Gwen Melincoff
Director
Leon Recanati
Director
Shmuel Rubinstein
Director
Ari Shamiss
Independent Director
Estery Giloz-Ran
Independent Director
Abraham Havron
Independent Director
Tuvia Shoham
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KMDA
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kamada Ltd. stock information, including NASDAQ:KMDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KMDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KMDA stock methods without spending real money on the virtual paper trading platform.